Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bochum – page 124

1 704 clinical trials in Bochum, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bochum at a glance
1 704
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 704 trials in Bochum

Open in trial search

Study on Caplacizumab and Immunosuppressive Therapy for Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Caplacizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Long-Term Safety of Seladelpar for Patients with Primary Biliary Cholangitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Seladelpar
  • Sponsor:Gilead Sciences Inc.

Neoplasm

Not recruiting

Study on the Effectiveness of Inavolisib, Atezolizumab, and Entrectinib in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Study of Ifinatamab Deruxtecan for Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Study of ianalumab versus placebo in adults with warm autoimmune hemolytic anemia who failed previous treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Novartis Pharma AG

Study on Durvalumab and Tremelimumab for Patients with Advanced Liver Cancer Not Treatable by Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Study of Lutetium (177Lu) Edotreotide compared to standard treatment in patients with aggressive Grade 2 and Grade 3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:ITM Solucin GmbH

Actinic keratosis

Not recruiting

Study on the Safety of Tirbanibulin and Diclofenac Sodium for Adults with Actinic Keratosis on the Face or Scalp

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Diclofenac Sodium
  • Sponsor:Almirall S.A.

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Celgene Corp.

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Glioma

Not recruiting

Study of Vorasidenib for Patients with Residual or Recurrent Grade 2 Glioma with IDH1 or IDH2 Mutation

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Vorasidenib
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bochum

What the registry says about research in the country

01 Dermatology Research

Clinical trials focusing on skin conditions, including studies for cutaneous lupus erythematosus, hidradenitis suppurativa, and plaque psoriasis. Novel therapeutic approaches are being evaluated to improve treatment outcomes for patients with chronic skin disorders.

  • Cutaneous Lupus Treatment
  • Hidradenitis Suppurativa Management
  • Plaque Psoriasis Therapy

Multiple studies are investigating new medications for moderate to severe cases of these conditions.

02 Oncology Studies

Innovative research in cancer treatment, particularly focusing on colorectal cancer, pancreatic cancer, gastric cancer, and non-small cell lung cancer. These trials are evaluating targeted therapies and combination treatments.

  • Metastatic Colorectal Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Advanced NSCLC

New therapeutic approaches combining immunotherapy with targeted treatments are being studied.

03 Cardiovascular and Metabolic Research

Studies focusing on heart failure prevention and chronic kidney disease management. Research includes innovative combination therapies and preventive approaches for high-risk patients.

  • Heart Failure Prevention
  • Chronic Kidney Disease
  • Post-COVID POTS

Trials are evaluating new treatment combinations to improve patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.